Fig. 1 · Structure

Documents & Downloads

BMS-707035

Cat. No. A10156 CAS 729607-74-3

HIV-1 integrase inhibitor

BMS-707035 is an HIV-1 integrase (IN) inhibitor. HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HIV-I integrase 15 nM

BMS-707035 Research Summary

This section summarizes 1 in vitro study of BMS-707035 from 1 published reference. In vitro models include HTLV-1 integrase.

BMS-707035 In Vitro Studies

HTLV-1 integrase was incubated with the study compound, and concerted integration bands were quantified by densitometry. The reported IC50 was 0.35 ± 0.074 μM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Concerted integration assay with HTLV-1 integrase

Cell-based study · HTLV-1 integrase [1]

HTLV-1 integrase was incubated with the study compound, and concerted integration bands were quantified by densitometry. The reported IC50 was 0.35 ± 0.074 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
concerted integration bands were quantified by densitometryIC50 IC50 = 0.35 ± 0.074 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
30 min room temperature incubation; 37°C for 30 min
Method
incubation
Vehicle
5% DMSO
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: BMS-707035

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Integrase Strand Transfer Assays (S8, S9, S11); Results > Inhibition Profiles of INSTIs in HTLV-1 IN Strand Transfer (S66); FIGURE 2 legend (S112); TABLE 1 (T1.h3, T1.r5)

concerted integration bands were quantified by densitometry: concerted integration bands were quantified by densitometry; comparator: absence of INSTIs — FIGURE 2 legend (S112); TABLE 1 (T1.h3, T1.r5)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 729607-74-3
Applications HIV-1 integrase inhibitor
Formula C17H19FN4O5S
Molecular Weight 410.4
SMILES
CN1C(=O)C(=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(C=C3)F)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 32 mg/mL (77.96 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BMS-707035 Research References

  1. [1] Barski MS, Minnell JJ, Maertens GN. Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors. Front Microbiol (2019). PMID: 31474960 DOI: 10.3389/fmicb.2019.01877 Source material

Added to your cart

View Cart Checkout
Loading...